Edition:
India

People: Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

0.34USD
21 Oct 2019
Change (% chg)

-- (--)
Prev Close
$0.34
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
88,394
52-wk High
$2.01
52-wk Low
$0.29

Kowalski, Mark 

Dr. Mark Kowalski, M.D. Ph.D. serves as Chief Medical Officer of the Company., since January 2017. Previously, Dr. Kowalski served as the Chief Medical Officer and Senior Vice President at Arbutus Biopharma (formerly Tekmira Pharmaceuticals), a biotechnology company, from August 2013 to September 2016. Prior to that, Dr. Kowalski worked at Gilead Sciences, Inc. from February to August 2013 following Gilead’s acquisition of YM BioSciences Inc., at which Dr. Kowalski had been Chief Medical Officer and Vice President of Regulatory Affairs from November 2010. Dr. Kowalski previously held the position of Chief Medical Officer of Viventia Biotech, a privately-held biotechnology company, which sought protection from creditors under the Companies’ Creditors Arrangement Act in April 2008 in Ontario, Canada. Dr. Kowalski holds a B.A. from Rutgers University and an M.D. and Ph.D. from the University of Kansas School of Medicine.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --